No Data
Citius Pharmaceuticals Entered Into Definitive Agreements For The Purchase Of An Aggregate Of 12M Shares Of Its Common Stock And Accompanying Warrants To Purchase Up To An Aggregate Of 12M Shares Of Its Common Stock, At A Purchase Price Of $0.25 Per...
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4
Citius Pharmaceuticals' Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy Rating
H.C. Wainwright Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4
Buy Rating for Citius Pharmaceuticals: Promising Clinical Results and Strong Financial Outlook
No Data
No Data